Suppr超能文献

取代的 2-苯基-1,2,4-三嗪-3,5(2,4)-二酮类似物的构效关系研究:针对三阴性乳腺癌的有效 eEF2K 降解剂的开发。

Structure-Activity Relationship Studies of Substituted 2-Phenyl-1,2,4-triazine-3,5(2,4)-dione Analogues: Development of Potent eEF2K Degraders against Triple-Negative Breast Cancer.

机构信息

Department of Medicinal Chemistry, Jiangsu Key Laboratory of Neuropsychiatric Diseases and College of Pharmaceutical Sciences, Soochow University, Suzhou 215123, China.

Department of Pharmacy, The Second Xiangya Hospital, Central South University, Changsha 410011, China.

出版信息

J Med Chem. 2024 Sep 12;67(17):15837-15861. doi: 10.1021/acs.jmedchem.4c01484. Epub 2024 Aug 29.

Abstract

eEF2K, an atypical alpha-kinase, is responsible for regulating protein synthesis and energy homeostasis. Aberrant eEF2K function has been linked to various human cancers, including triple-negative breast cancer (TNBC). However, limited cellular activity of current eEF2K modulators impedes their clinical application. Based on the 2-phenyl-1,2,4-triazine-3,5(2,4)-dione scaffold of our hits and , structure-activity relationship analysis led to the discovery of several more active derivatives (e.g., , , and ) in inhibiting the viability of TNBC cell line MDA-MB-231. Moreover, the most potent compound significantly suppresses the viability, proliferation, and migration of both MDA-MB-231 and HCC1806 cell lines. Mechanistically, compound has a high binding affinity for the eEF2K protein and effectively induces its degradation. Additionally, exerts a comparable tumor-suppressive effect to paclitaxel in an MDA-MB-231 cell xenograft mouse model with no obvious toxicity, demonstrating that compound could be developed as a potential novel therapeutic for TNBC treatment.

摘要

真核延伸因子 2 激酶(eEF2K)是一种非典型的α-激酶,负责调节蛋白质合成和能量稳态。异常的 eEF2K 功能与各种人类癌症有关,包括三阴性乳腺癌(TNBC)。然而,目前 eEF2K 调节剂的细胞活性有限,阻碍了它们的临床应用。基于我们的命中化合物和的 2-苯基-1,2,4-三嗪-3,5(2,4)-二酮骨架,结构-活性关系分析发现了几种更具活性的衍生物(例如,、和),它们能够抑制 TNBC 细胞系 MDA-MB-231 的活力。此外,最有效的化合物显著抑制 MDA-MB-231 和 HCC1806 细胞系的活力、增殖和迁移。在 MDA-MB-231 细胞异种移植小鼠模型中,化合物具有与紫杉醇相当的肿瘤抑制作用,且没有明显的毒性,表明化合物可能被开发为治疗 TNBC 的一种潜在新型治疗药物。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验